Kaposi sarcoma-associated immune reconstitution inflammatory syndrome: In need of a specific case definition

Clinical Infectious Diseases

Volumn 55, Issue 1, 2012, Pages 157-158

  Letang, Emilio ^a   Naniche, Denise ^a   Bower, Mark ^c   Miro, Jose M ^b  

^a CENTRE FOR RESEARCH IN ENVIRONMENTAL EPIDEMIOLOGY CREAL   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; VIRUS DNA;

CANCER CHEMOTHERAPY; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; DISEASE COURSE; EUROPE; HERPES VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INCIDENCE; KAPOSI SARCOMA; LETTER; MULTICENTER STUDY (TOPIC); NONHUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; UNITED KINGDOM; VIRUS LOAD;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; FEMALE; HUMANS; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; MALE;

EID: 84862224372     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis308     Document Type: Letter

References (10)

1. Achenbach CJ, Harrington RD, Dhanireddy S, Crane HM, Casper C, Kitahata MM. Paradoxical immune reconstitution inflammatory syndrome in HIV-infected patients treated with combination antiretroviral therapy after AIDS-defining opportunistic infection. Clin Infect Dis 2011; 54:424-33.
2. Bower M, Nelson M, Young AM, et al. Immune reconstitution inflammatory syndrome associated with Kaposi's sarcoma. J Clin Oncol 2005; 23:5224-8.
3. Letang E, Almeida JM, Miro JM, et al. Predictors of immune reconstitution inflammatory syndrome-associated with Kaposi sarcoma in Mozambique: a prospective study. J Acquir Immune Defic Syndr 2010; 53:589-97.
4. Letang E, Lewis J, Bower M, et al. Incidence and predictors of Kaposi sarcoma associated with immune reconstitution inflammatory syndrome in sub-Saharan Africa and the UK. 18th Conference on Retroviruses and Opportunistic Infections (CROI). Boston, Massachusetts, 2011 (abstract 857).
5. Campbell TB, Borok M, Gwanzura L, et al. Relationship of human herpesvirus 8 peripheral blood virus load and Kaposi's sarcoma clinical stage. AIDS 2000; 14: 2109-16.
6. Krown SE, Testa MA, Huang J. AIDSrelated Kaposi's sarcoma: prospective validation of the AIDS Clinical Trials Group staging classification. AIDS Clinical Trials Group Oncology Committee. J Clin Oncol 1997; 15:3085-92.
7. El Amari EB, Toutous-Trellu L, Gayet-Ageron A, et al. Predicting the evolution of Kaposi sarcoma, in the highly active antiretroviral therapy era. AIDS 2008; 22: 1019-28.
8. Muller M, Wandel S, Colebunders R, Attia S, Furrer H, Egger M. Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect Dis 2010; 10:251-61.
9. Shelburne SA, Visnegarwala F, Darcourt J, et al. Incidence and risk factors for immune reconstitution inflammatory syndrome during highly active antiretroviral therapy. AIDS 2005; 19:399-406.
10. Leidner RS, Aboulafia DM. Recrudescent Kaposi's sarcoma after initiation of HAART: a manifestation of immune reconstitution syndrome. AIDS Patient Care STDS 2005; 19:635-44.